Solid Lipid Nanoparticle Encapsulation of the IDO1 Inhibitor EOS200271 Enhances Antitumor Efficacy Against Oral Squamous Cell Carcinoma.
Zheng Genggeng G, Lin Shuoqi S, Yan Yuxiang Y, Lu Youguang Y et al.
Oral squamous cell carcinoma (OSCC) is an aggressive malignancy with poor long-term survival. Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive therapeutic target in OSCC, but the clinical utility of the IDO1 inhibitor EOS200271 is constrained by poor cellular uptake and rapid clearance. We investigated the antitumor activity of EOS200271 against OSCC and developed a PEG-modified solid lipid nanoparticle formulation (PEG-SL@EOS) to enhance its antitumor efficacy. PEG-SL@EOS was characterized for particle size, zeta potential, encapsulation efficiency, drug loading, and release behavior. Anti-OSCC activity was assessed via CCK-8, EdU incorporation, and apoptosis assays. IDO1 inhibition was measured by kynurenine ELISA, and cellular uptake by flow cytometry. In vivo efficacy was examined in orthotopic (nude) and subcutaneous (BALB/c) xenograft models. Biosafety was evaluated through body weight monitoring, histopathology, and hemolysis testing. Free EOS200271 moderately inhibited OSCC cell proliferation and induced apoptosis but was limited by low cellular uptake. PEG-SL@EOS substantially enhanced cellular uptake, showed greater anti-proliferative and pro-apoptotic activity, and more effectively suppressed tumor growth in both models. Mechanistically, PEG-SL@EOS led to greater kynurenine reduction than free drug, suggesting enhanced IDO1 inhibition. No significant body weight loss, organ damage, or hemolysis was observed. Encapsulation of EOS200271 in PEG-modified solid lipid nanoparticles enhances its antitumor efficacy with favorable biosafety. This strategy warrants further investigation toward clinical applications of IDO1-targeted therapy in OSCC.